Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib as adjuvant therapy in EGFR-mutated lung adenocarcinoma
NCT02125240Phase 3Unknown
- Sponsor
- Betta Pharmaceuticals
- Start
- Sep 2014
- Primary completion
- Dec 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of icotinib in lung adenocarcinoma, sponsored by Betta Pharmaceuticals. Status: unknown.
02
Drugs
icotinib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT02125240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02125240.